DirectoryMix Web Resources » Article Details

MOSAID Sells Selected Patents to SAtech Group A.B. Limited Liability Company - Read More

Date Added: May 01, 2008 04:51:03 AM
OTTAWA, ONTARIO-- - MOSAID Technologies Inc. today announced that it has completed the sale of 19 patent families, comprised of U.S. patents and applications and corresponding foreign counterparts, to SAtech Group A.B.

Category: Reference » Patents


No comments are posted yet


 
Name:*
Email:*
Website:  (optional)
Comment:*
(html and bb codes are filtered and not allowed)

Do the math:*CAPTCHA - Do The Math
 

Related Articles

Qualcomm Again Held in Contempt of Injunction on 3G Cellular Products Previously Found to Infringe Broadcom Patent

Broadcom Corporation , a global leader in semiconductors for wired and wireless communications, announced that a federal judge yesterday found Qualcomm Incorporated in contempt of an injunction entered last December that was designed to prevent Qualcomm f

Broadcom Names Arthur Chong as General Counsel

Broadcom Corporation , a global leader in semiconductors for wired and wireless communications, announced that Arthur Chong has been named Senior Vice President, General Counsel and Secretary, effective today.

Eighth Assisted Global Positioning System Patent Issued to TCS

TeleCommunication Systems, Inc. (NASDAQ: TSYS), a leading provider of mission-critical wireless communications, today announced that the U.S. Patent and Trademark Office has issued patent number 7,411,546 for "Other Cell Sites Used As Reference Point To

Innovation grants slashed to save $707m: Budget 08

Commercial Ready, a SME grants program that subsidised innovation and commercialisation, was scrapped in this week's federal Budget — a move that will save AU$707 million over four years.

Pluristem's President and CEO to be Keynote Speaker at The 4th Annual Stem Cells Asia Congress

NEW YORK----Pluristem Therapeutics Inc. , a bio-therapeutics company dedicated to the commercialization of non-personalized cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced that Mr.